RP-HPLC Method for Simultaneous Determination of Valsartan and Fenofibrate from PPI Dendrimer

P. SURESHKUMAR^{1,*}, J. VIJAYA RATNA² and N. HEMATHEERTHANI³

¹Nova College of Pharmaceutical Education and Research, Jupudi, Ibrahimpatnam-521 456, India

²Department of Pharmaceutical Sciences, College of Science and Technology, Andhra University, Visakhapatnam-530 003, India

³Gurram Balnarasiah Institute of Pharmacy, Ghatkear Mandal, RR District-501 301, India

*Corresponding author: E-mail: pskumar1974@gmail.com

(Received: 12 March 2012;

Accepted: 9 January 2013)

AJC-12677

The present study aimed at synthesizing PPI dendrimer and loading dual drug followed by developing stability indicating reversed-phase HPLC method and subsequent validation for simultaneous estimation of valsartan and fenofibrate. The proposed RP-HPLC method utilizes a Nucleosil 100, 5 μ m, C₈, 250 $\times$ 4.0 mm column, mobile phase consisting of methanol : 1 % orthophosphoric acid : acetonitrile (45:30:25) and UV detection at 247 nm. The described method was linear over a range of 10-50 μ g/mL for valsartan and 3-15 μ g/mL for fenofibrate. The mean recoveries were 99.91 and 100.53 % for valsartan and fenofibrate, respectively. Statistical data's were used to check the intermediate precision data obtained under different experimental setups. The calculated value was found to be less than critical value.

Key Words: Valsartan, Fenofibrate, Dendrimer, Simultaneous.

INTRODUCTION

Dendrimer represents a novel type of polymeric material. It is also known as starburst¹ or cascade² or molecular trees³ or arborols, or polymers. They attract the increasing attention of pharmaceutical researchers because of their unique structure, high degree of control over molecular weight and the shape that has led to the synthesis of unimolecular micelles^{4,5}. 5G EDA-PPI dendrimers were synthesized by reported method^{6,7}.

The chemical formula of valsartan is N-(1-oxopentyl)-N-[[2-(1H-tetrazol-5-yl) [1,1-biphenyl]-4-yl]methyl]-L-valine (Fig. 1). Valsartan is a potent, highly selective, and orally active antagonist at the angiotensin II AT1-receptor that is used for the treatment of hypertension. Few methods appeared in the literature for the determination of valsartan individually based on high-performance liquid chromatography⁸⁻¹⁰. Sampath *et al.*¹¹ described identification and characterization of potential impurities of valsartan AT1 receptor antagonist. There has been some of estimation of assays of analyte in human plasma including the use of liquid chromatography¹²⁻¹⁵, a gas chromatographic, mass spectroscopic¹⁶ and some combination with other drugs using high pressure liquid chromatography and derivative spectroscopy¹⁷⁻²².

Fenofibrate (Fig. 2), isopropyl 2-[4-(4-chlorobenzoyl) phenoxy]-2-methylpropionate, is fibric acid derivative, used for regulating plasma lipids and treatment of hyperlipopro-

teinaemias²³. The literature survey reveals that fenofibrate was analyzed in environmental water samples using solid phase extraction followed by GC-MS^{24,25} or HPLC electrospray ionization MS-MS²⁴. HPLC was used for determination of fenofibrate²⁶⁻²⁸, its metabolites²⁹⁻³³ and related impurities^{34,35}. Other HPLC methods for assay and purity of fenofibrate and an NMR method for related compounds in fenofibrate raw materials were reported³⁶. There are no simultaneous method for the determination of valsartan and fenofibrate. This study aimed to develop a simultaneous method for the estimation of both the drugs by RP-HPLC method.

Fig. 1. Structure of valsartan

Scheme-I

Fig. 2. Structure of fenofibrate

EXPERIMENTAL

Shimadzu LC-2010 HT with liquid chromatograph, Mettler Toledo electronic analytical balance, transsonic digital S (Sonicator), Chromatographic software-CLASS-VP and Nucleosil 100, 5 μm , C₈, 250 $\times$ 4.0 mm column was used as a stationary phase, Perkin-Elmer IR spectroscope and Bruker DRX, USA.

Valsartan and fenofibrate were supplied by Microlabs limited, Bangalore. Ethylenediamine, acrylonitrile, Raney nickel, HPLC grades methanol, AR grade *ortho* phosphoric acid, hydrochloric acid, sodium hydroxide, hydrogen peroxide were procured from E. Merck.

Synthesis of 5G EDA-PPI dendrimers: 5G EDA-PPI dendrimers were synthesized by reported method^{23,24}. In brief, ethylenediamine was used as initiator core and acrylonitrile was added to it in a double Michael addition reaction method to produce half generation (-CN terminated), followed by heterogeneous hydrogenation using Raney nickel as catalyst to produce full generation (-NH₂) dendrimers. The reaction sequence was repeated cyclically to produce PPI dendrimers up to fifth generation (PPI-5G) as shown in Fig. 1 (Scheme-I). Synthesized dendrimers were characterized by IR (Perkin-Elmer IR spectroscope) and NMR spectroscopy (Bruker DRX, USA).

Drug loading in formulations: The known molar concentrations of EDA-PPI dendrimer- $(\text{NH}_2)_{64}$ and valsartan conjugated 5.0G EDA-PPI dendrimers were dissolved separately in methanol and mixed with methanolic solution of fenofibrate (100 μmol). The mixed solutions were incubated with slow magnetic stirring (50 rpm) using Teflon beads for 24 h. These solutions were twice dialyzed in cellulose dialysis bag (MWCO 1000 Da Sigma, Germany) against double distilled water under

sink conditions for 10 min to remove free drug from the formulations, which was then estimated spectrophotometrically (λ_{max} 475 nm) to determine indirectly the amount of drug loaded within the system. The dialyzed formulations were lyophilized and used for further characterization.

Preparation of standard stock solution: About 20 mg of standard Valsartan and fenofibrate were weighed accurately and transferred to a separate 100 mL volumetric flask with mobile phase and sonicated for 10 min and made up to graduation with mobile phase. The final concentration was prepared by diluting suitable aliquates.

Selection and preparation of mobile phase: Pure drug of valsartan and fenofibrate were injected into the HPLC system and run in different solvent systems. It was found that methanol: 1 % *ortho* phosphoric acid: acetonitrile gives satisfactory results as compared to other mobile phases. Finally, the optimal composition of the mobile phase employed was 45:30:25 and UV detection at 247 nm. The prepared mobile phase was ultrasonicated for 20 mins.

Selection of analytical wavelength: By appropriate dilution of standard stock solution with mobile phase, various concentrations of Valsartan and fenofibrate were prepared separately. The solutions were scanned using the double beam UV visible spectrophotometer in the spectrum mode between the wavelength ranges of 400 nm to 200 nm and 247 nm which was selected as the analytical wavelength for further analysis.

RESULTS AND DISCUSSION

System suitability: System suitability parameters were calculated at the start of study of each validation parameter. The values of system suitability results obtained during the entire study are recorded in Table-1.

Linearity: Linearity was determined at five levels over the range of 10-50 $\mu\text{g/mL}$ for Valsartan and 3-15 $\mu\text{g/mL}$ for fenofibrate of test concentration. Each linearity solution was injected in triplicate. The mean area at each level is calculated and a graph of mean area versus concentration is plotted. The correlation co-efficient (*r*), Y-intercept, slope of regression line, residual sum of squares are calculated and recorded in Table-1. The plot of peak area response against concentration is

TABLE-1
VALIDATION DATA FOR VAL AND FB

a) Regression characteristics of the proposed HPLC method				
Linearity experiment (n=5)	VAL		FB	
Range (µg/mL)	10-50		3-15	
Mean 'r' value	0.999		0.999	
Slope	4394.9		33755	
Intercept	671.43		3739.3	
b) Results of accuracy using proposed method				
Accuracy (n = 3)	VAL		FB	
	% recovery		% recovery	
Level 1	98.87		101.09	
Level 2	98.24		98.68	
Level 3	98.92		101.44	
Mean % recovery (n=9)	98.68		100.40	
% R.S.D	0.3841		1.4966	
c) Results of precision and intermediate precision for VAL and FB				
	VAL		FB	
	Mean assay (%) /(%) RSD		Mean assay (%)/ (%) RSD	
Precision (n=6)	100.25 / 0.8762		99.65 / 1.2634	
Intermediate precision (n=6)	100.87 / 0.7856		99.88 / 1.1452	
d) Results of solution stability for VAL and FB				
	VAL (% recovery)		FB (% recovery)	
	Room temp.	4 °C	Room temp.	4 °C
Initial	100.11	100.25	99.97	99.87
After 4 h	99.95	99.87	99.91	99.12
After 8 h	98.98	99.98	99.12	99.25
After 12 h	98.89	98.92	98.56	98.76
After 24 h	99.85	99.67	98.17	98.12
VAL = Valsartan; FB = Fenofibrate.				

VAL = Valsartan; FB = Fenofibrate.

presented in Figs. 4 and 5. The Beer Lambert's law was obeyed in the concentration range 10-50 µg/mL for Valsartan and 3-15 µg/mL for fenofibrate. The linearity of calibration graphs and adherence of the system to Beer's law was validated by high value of correlation coefficient.

Specificity: The specificity of the HPLC method was determined by complete separation of both valsartan and fenofibrate in the presence of its degradation products. There were no interference from sample and its degraded products the peak purity of both Valsartan and fenofibrate were 0.9991 and 0.9998. It shows that developed analytical method is specific for the analysis of both Valsartan and fenofibrate.

Precision: The precision of the method was established by carrying out the analysis of the analyte (n = 6) using the proposed method. The chromatogram for standard was given in Fig. 3. The value of standard deviation shows that the method is precise. The results obtained are presented in Table-1.

Recovery studies: To check the accuracy of the proposed method, recovery studies were carried out at 50, 100 and 150 % of the test concentration as per ICH guidelines. The recovery study was performed three times at each level.

Robustness of method: The robustness of the developed method was studied by making small deliberate variations in the method parameters such as the small components in the mobile phase, flow rate, wavelength and the column temperature. The results of the robustness study are within the critical value.

Ruggedness: Ruggedness test was determined between two different analysts, instruments and columns. The value of

Fig 3. Typical chromatogram of valsartan and fenofibrate

Fig 4: Linearity of valsartan

Fig. 5. Linearity of fenofibrate

percentage RSD was below 2.0 %, exhibits the ruggedness of developed analytical method.

Solution stability studies: The sample solution was prepared at test concentration and initial assay was determined. Solution was stored up to 24 h at room temperature and about 4 °C and assay was determined at 4, 8, 12 and 24 h against freshly prepared standard and also analyzed about 4 °C at 24 h. The assay obtained at different time intervals was compared with the initial assay value and recorded. The relative standard deviation was found below 2 %. It proves that both standard and sample solutions are stable up to 24 h at room temperature and at 4 °C and results are given in Table-1.

ACKNOWLEDGEMENTS

The authors thankful to Microlabs Limited, Bangalore for providing gift sample of valsartan and fenofibrate. The authors thankful to the management of Nova College of Pharmaceutical Education and Research, Jupudi for providing necessary facilities to carry out this research work.

REFERENCES

1. D.A. Tomalia and H.D. Durst, in ed.: E. Weber, *Supramolecular Chemistry I-Directed Synthesis and Molecular Recognition*. In *Topics in Current Chemistry*; Ed.; Springer-Verlag: Berlin, vol. 165, p. 193 (1993).
2. P.B. Smith, S.J. Martin, M.J. Hall and D.A. Tomalia, in ed.: J. Mitchell, *Characterization of the Structure and Synthetic Reactions of Polyamidoamine "STARBURST" Polymers*. In *Applied Polymer Analysis Characterization*; Hanser: Munich, pp. 357-385 (1987).
3. J.M.J. Frechet, S. Matuszczak, H.D.H. Stover, B. Reck and C.G. Willson, *The Electrophilic Aromatic Substitution Approach*. In *Polymers in Microlithography*; ACS Symposium Series 412; American Chemical Society: Washington, DC, pp. 74-86 (1989).
4. D.A. Tomalia, J.R. Dewald, M.R. Hall, S.J. Martin and P.P. Smith, *Preprints of the 1st SPSJ International Polymer Conference*, Society of Polymer Science Japan, Kyoto, p. 65 (1984).
5. H. Staudinger, In *From Organic Chemistry to Macromolecules*; Wiley Interscience: New York (1970).
6. D. Brabender-Van Den Berg and E.M. Meijer, *Angew. Chem. Int. Ed. Engl.*, **32**, 1665 (1993).
7. D. Bhadra, A.K. Yadav, S. Bhadra and N.K. Jain, *Int. J. Pharm.*, **295**, 221 (2005).
8. E. Francotte, A. Davatz and P. Richert, *J. Chromatogr. B: Biomed. Appl.*, **686**, 77 (1996).
9. Z.Z. Piao, E.S. Lee, H.T. Tran and B.J. Lee, *Arch. Pharm. Res.*, **31**, 1055 (2008).
10. G. Iriarte, N. Ferreiros, I. Ibarrondo, R.M. Alonso and M. Itxaso Maguregui, *J. Sep. Sci.*, **30**, 2231 (2007).
11. A. Sampath, A.R. Reddy, B. Yakambaram, A. Thirupathi, M. Prabhakar, P.P. Reddy and V.P. Reddy, *J. Pharm. Biomed. Anal.*, **50**, 405 (2009).
12. D. Zhang, X. Du, M. Liu, H. Li, Y. Jiang, L. Zhao and J. Gu, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, **863**, 223 (2008).
13. J. Macek, J. Klima and P. Ptacek, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, **832**, 169 (2006).
14. N. Ferreiros, G. Iriarte, R.M. Alonso, R.M. Jimenez and E. Ortiz, *J. Sep. Sci.*, **31**, 667 (2008).
15. A. Zarghi, A. Shafaati, S.M. Foroutan and H. Movahed, *Sci. Pharm.*, **76**, 439 (2008).
16. H.H. Maurer and T. Kraemer, *Arlt. Ther. Drug Monit.*, **20**, 706 (1998).
17. I.E. Panderi and P.M. Parissi, *J. Pharm. Biomed. Anal.*, **21**, 1017 (1999).
18. D. Farthing, I. Fakhry, E.B. Ripley and D. Sica, *J. Pharm. Biomed. Anal.*, **17**, 1455 (1998).
19. K. Richter, R. Oertel and W. Kirch, *J. Chromatogr. A*, **729**, 293 (1996).
20. C.V. Prasad, C. Parihar, K. Sunil and P. Parimoo, *J. Pharm. Biomed. Anal.*, **17**, 877 (1998).
21. N.J. Shah, B.N. Suhagia, R.R. Shah and N.M. Patel, *Indian J. Pharm. Sci.*, **71**, 72 (2009).
22. B. Kocyigit-Kaymakcoglu, S. Unsalan and S. Rollas, *Pharmazie*, **61**, 586 (2006).
23. S.C. Sweetman, *Martindale-The Complete Drug Reference*, Pharmaceutical Press, edn 33 (2002).
24. K. Reddersen and T. Heberer, *J. Sep. Sci.*, **26**, 1443 (2003).
25. F. Sacher, F.T. Lange, H.J. Brauch and I. Blankenhorn, *J. Chromatogr. A*, **938**, 199 (2001).
26. *British Pharmacopeia*, Her Majesty Stationery Office, London (2001).
27. *European Pharmacopoeia*, Council of Europe, Strasbourg, France, edn. 4 (2002).
28. L.A. Romanyshyn and P.R. Tiller, *J. Chromatogr. A*, **928**, 41 (2001).
29. G.R. Fan, M. Lin, Z.X. Zhang and D.K. An, *Yaowu Fenxi Zazhi*, **20**, 231 (2000).
30. B. Streel, P. Hubert and A. Ceccato, *J. Chromatogr. B Biomed. Appl.*, **742**, 391 (2000).
31. S. Abe, K. Ono, M. Mogi and T. Hayashi, *Yakugaku Zasshi*, **118**, 447 (1998).
32. L.D. Masnatta, L.A. Cuniberti, R.H. Rey and J.P. Werba, *J. Chromatogr. B: Biomed. Appl.*, **687**, 437 (1996).
33. A.C. Ramusino and A. Carozzi, *J. Chromatogr. Biomed. Appl.*, **56**, 419 (1986).
34. R.N. Rao and V. Nagaraju, *J. Pharm. Biomed. Anal.*, **33**, 335 (2003).
35. X. Ji and C. Ye, *ZhongguoYaoke Daxue Xuebao*, **18**, 284 (1987).
36. P.M. Lacroix, B.A. Dawson, R.W. Sears, D.B. Black, T.D. Cyr and J.C. Ethier, *J. Pharm. Biomed. Anal.*, **18**, 383 (1998).